Cargando…

Retention in the Austrian opioid agonist treatment system: a national prospective cohort study

BACKGROUND: Retention in care is a prerequisite for successful recovery, especially for a chronic condition like opioid dependence. Though retention varies greatly depending on the different substitution medication and treatment model, treatment retention is used as an indicator of treatment quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Busch, Martin, Klein, Charlotte, Uhl, Alfred, Haltmayer, Hans, Cabanis, Maurice, Westenberg, Jean Nicolas, Vogel, Marc, Krausz, R. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903033/
https://www.ncbi.nlm.nih.gov/pubmed/33627159
http://dx.doi.org/10.1186/s12954-021-00473-9
_version_ 1783654658211840000
author Busch, Martin
Klein, Charlotte
Uhl, Alfred
Haltmayer, Hans
Cabanis, Maurice
Westenberg, Jean Nicolas
Vogel, Marc
Krausz, R. Michael
author_facet Busch, Martin
Klein, Charlotte
Uhl, Alfred
Haltmayer, Hans
Cabanis, Maurice
Westenberg, Jean Nicolas
Vogel, Marc
Krausz, R. Michael
author_sort Busch, Martin
collection PubMed
description BACKGROUND: Retention in care is a prerequisite for successful recovery, especially for a chronic condition like opioid dependence. Though retention varies greatly depending on the different substitution medication and treatment model, treatment retention is used as an indicator of treatment quality and effectiveness of care on a system and individual level. To monitor the overall quality of the Austrian opioid agonist treatment (OAT) system and to monitor patient satisfaction within the system, a new online-based registry called “eSuchmittel” was introduced in Austria at the beginning of 2011. The objective of this study is to analyze retention rates within the Austrian treatment system and to identify patient characteristics associated with retention, using data collected by the substitution registry. METHODS: The complete Austrian sample of 4778 registered patients starting treatment between 1.1.2011 to 31.12.2012 were included in the prospective cohort study using data from the Austrian substitution registry. For the statistical analysis, multivariate Cox Regression and Kaplan–Meier survival analysis were used to evaluate retention in treatment. RESULTS: The retention rate of the total cohort after two years was around 61%. Retention rates were significantly lower for men (exp(B) = .806, 95% CI 0.714–0.908) and significantly higher for patients aged 30 and older (exp(B) = 1.155, 95% CI 1.044–1.279), among patients located in Vienna (exp(B) = 1.439, 95% CI 1.273–1.626) and among patients prescribed oral slow-release morphine (SROM) (exp(B) = 2.141, 95% CI 1.885–2.430). CONCLUSIONS: Average retention in the Austrian system is high in comparison to international retention rates. Nationally, SROM demonstrates higher treatment retention when compared to other available substitution medications. Sociodemographic and regional indicators also contribute to higher retention in care. A systematic monitoring of retention rates within a national registry is an important tool helping to evaluate the quality of care. In this study, the Austrian OAT system proves very high retention in care, an important success criterion.
format Online
Article
Text
id pubmed-7903033
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79030332021-02-24 Retention in the Austrian opioid agonist treatment system: a national prospective cohort study Busch, Martin Klein, Charlotte Uhl, Alfred Haltmayer, Hans Cabanis, Maurice Westenberg, Jean Nicolas Vogel, Marc Krausz, R. Michael Harm Reduct J Research BACKGROUND: Retention in care is a prerequisite for successful recovery, especially for a chronic condition like opioid dependence. Though retention varies greatly depending on the different substitution medication and treatment model, treatment retention is used as an indicator of treatment quality and effectiveness of care on a system and individual level. To monitor the overall quality of the Austrian opioid agonist treatment (OAT) system and to monitor patient satisfaction within the system, a new online-based registry called “eSuchmittel” was introduced in Austria at the beginning of 2011. The objective of this study is to analyze retention rates within the Austrian treatment system and to identify patient characteristics associated with retention, using data collected by the substitution registry. METHODS: The complete Austrian sample of 4778 registered patients starting treatment between 1.1.2011 to 31.12.2012 were included in the prospective cohort study using data from the Austrian substitution registry. For the statistical analysis, multivariate Cox Regression and Kaplan–Meier survival analysis were used to evaluate retention in treatment. RESULTS: The retention rate of the total cohort after two years was around 61%. Retention rates were significantly lower for men (exp(B) = .806, 95% CI 0.714–0.908) and significantly higher for patients aged 30 and older (exp(B) = 1.155, 95% CI 1.044–1.279), among patients located in Vienna (exp(B) = 1.439, 95% CI 1.273–1.626) and among patients prescribed oral slow-release morphine (SROM) (exp(B) = 2.141, 95% CI 1.885–2.430). CONCLUSIONS: Average retention in the Austrian system is high in comparison to international retention rates. Nationally, SROM demonstrates higher treatment retention when compared to other available substitution medications. Sociodemographic and regional indicators also contribute to higher retention in care. A systematic monitoring of retention rates within a national registry is an important tool helping to evaluate the quality of care. In this study, the Austrian OAT system proves very high retention in care, an important success criterion. BioMed Central 2021-02-24 /pmc/articles/PMC7903033/ /pubmed/33627159 http://dx.doi.org/10.1186/s12954-021-00473-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Busch, Martin
Klein, Charlotte
Uhl, Alfred
Haltmayer, Hans
Cabanis, Maurice
Westenberg, Jean Nicolas
Vogel, Marc
Krausz, R. Michael
Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title_full Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title_fullStr Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title_full_unstemmed Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title_short Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
title_sort retention in the austrian opioid agonist treatment system: a national prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903033/
https://www.ncbi.nlm.nih.gov/pubmed/33627159
http://dx.doi.org/10.1186/s12954-021-00473-9
work_keys_str_mv AT buschmartin retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT kleincharlotte retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT uhlalfred retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT haltmayerhans retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT cabanismaurice retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT westenbergjeannicolas retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT vogelmarc retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy
AT krauszrmichael retentionintheaustrianopioidagonisttreatmentsystemanationalprospectivecohortstudy